TABLE 1

Patient Demographics and Clinical Characteristics

VariableData
Sex
 Male9 (69.2)
 Female4 (30.8)
Age (y)63 (51–71)
Nephrectomy
 Yes11 (84.6)
 No2 (15.4)
Histology
 Pure clear cell12 (92.3)
 Mixed1 (7.7)
World Health Organization performance
 04 (30.8)
 12 (15.4)
 27 (53.8)
Tumor sites
 Number4 (2–7)
 Kidney6 (46.2)
  Primary2 (15.4)
  Local recurrence2 (15.4)
  Contralateral2 (15.4)
 Lung9 (69.2)
 Lymph node7 (53.8)
 Bone6 (46.2)
 Liver5 (38.5)
 Adrenal4 (30.8)
 Muscle4 (30.8)
 Other10 (76.9)
Previous treatment
 Tyrosine kinase inhibitor8 (61.5)
 Tyrosine kinase inhibitor and interferon alfa ± bevacizumab2 (15.4)
 Other3 (23.1)
  • Qualitative data are expressed as number followed by percentage in parentheses; continuous data are expressed as median followed by range in parentheses.